Revenue
2023
2024
2025
EUPRAXIA PHARMACEUTICALS INC. (EPRX)
Price—Loading quote
Net income
2022
2023
2024
2025
Free cash flow
No reported data
Total cash / debt
CashTotal debt
2021
2022
2023
2024
2025
Financial statements
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | — |
| Research & development | $21.3M | $16.1M | $20.4M | $13.6M |
| Operating expenses | $38.4M | $27.0M | $27.8M | $17.6M |
| Net income | −$38.6M | −$25.5M | −$28.2M | −$18.5M |
| Basic EPSper diluted share | -$1.03 | -$0.76 | -$1.17 | -$0.96 |
| Diluted EPSper diluted share | -$1.03 | -$0.76 | -$1.17 | -$0.96 |